Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26/06/26	USD 0.3602	-1.42%	176,532
25/06/26	USD 0.3654	-0.79%	128,599
24/06/26	USD 0.3683	-3.56%	194,913
23/06/26	USD 0.3819	0.00%	173,282

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.3602USD

Average target price

1.500USD

Spread / Average Target

+316.44%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 06:00:00 27/06/26 am AEST			5-day change	1st Jan Change
0.3602 ^USD	-1.42%		-5.66%	-29.37%

19/06	Scienture Holdings Expands Arbli Payor Coverage and Commercial Access	CI
09/06	Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team	CI

Market Cap	14.64M 12.83M 11.83M 11.07M 20.77M 1.38B 21.2M 142M 55.01M 682M 54.96M 53.76M 2.37B	P/E 2026 *	-1.2x	P/E 2027 *	-6x
Enterprise Value	14.64M 12.83M 11.83M 11.07M 20.77M 1.38B 21.2M 142M 55.01M 682M 54.96M 53.76M 2.37B	EV / Sales 2026 *	2.86x	EV / Sales 2027 *	0.85x
Free-Float	86.69%	Yield 2026 *	-	Yield 2027 *	-

19/06	Scienture Holdings Expands Arbli Payor Coverage and Commercial Access	CI
09/06	Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team	CI
02/06	Scienture Secures US Patent Protection for Rezenopy Through 2041	MT
30/05	Scienture - Eric Sherb resigns as CFO effective May 26, 2026	RE
30/05	Scienture Holdings, Inc. Announces CFO Changes, Effective May 26, 2026	CI
16/05	Scienture Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
07/05	Scienture secures $11.0 million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of research and development pipeline	RE
07/05	Scienture Holdings, Inc. Secures $11 Million in Non-Dilutive Debt Financing	CI
27/04	Scienture Holdings, Inc. announced that it has received $11 million in funding	CI
31/03	Scienture reports year end 2025 financial results and provides business update	RE
30/03	Scienture Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/03	Scienture Holdings, Inc. Auditor Raises 'Going Concern' Doubt	CI
12/03	Scienture Broadens Commercial Access for Rezenopy, Highest-Dose Fda-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching over 5,000 U.S. Institutions	CI

15/08/25	Top Midday Decliners	MT
01/06/23	EF Hutton Assumes Trxade Health at Buy With $1.25 Price Target	MT
29/03/23	Maxim Adjusts Price Target on Trxade Health to $1.75 From $2.50, Maintains Buy Rating	MT
11/05/22	Maxim Adjusts Price Target for TRxADE Health to $4 From $7, Maintains Buy Rating	MT
30/03/22	Maxim Adjusts TRxADE HEALTH's Price Target to $7 from $11, Maintains Buy Rating	MT

Scienture Holdings, Inc. Stock

Stocks

SCNX

US80880X1046

Pharmaceuticals

Valuation: Scienture Holdings, Inc.

Chart: Scienture Holdings, Inc.

Latest news : Scienture Holdings, Inc.

Last Transcript: Scienture Holdings, Inc.

Analysts' recommendations: Scienture Holdings, Inc.

Press Releases: Scienture Holdings, Inc.

Quotes and Performance

Course Extremes

Latest insider transactions

Pharmaceuticals Wholesale

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

18/06	SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide	AQ
09/06	SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team	AQ
04/06	SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC	AQ
02/06	SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041	AQ
18/05	SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion	AQ

1 day	-1.42%
1 week	-5.66%
Current month	-12.78%
1 month	-14.01%
3 months	-13.62%
6 months	-28.40%
Current year	-29.37%

1 week	0.36	0.4
1 month	0.31	0.43
Current year	0.24	0.64
1 year	0.24	2.6
3 years	0.24	13.42
5 years	0.24	13.42
10 years	0.24	13.42

Date	Insider	Type	Main position	Quantity	% Market Cap.
19/09/24	Narasimhan Mani	Conversion	Director	2,927,538	167.2839%
19/09/24	Shankar Hariharan	Conversion	Chief Executive Officer	3,853,296	220.1831%
25/07/24	Narasimhan Mani	Other	Director	57,977	4.1225%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCIENTURE HOLDINGS, INC.	-1.42%	-5.66%	-61.50%	-	14.64M
MCKESSON CORPORATION	-0.04%	+1.72%	+5.20%	+83.89%	89.39B
CARDINAL HEALTH, INC.	+1.35%	+7.28%	+42.31%	+153.62%	55.72B
SIGMA HEALTHCARE LIMITED	+1.08%	+1.45%	-6.35%	+239.39%	22B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	-3.11%	-3.90%	-13.86%	-28.38%	7.63B
HUADONG MEDICINE CO., LTD	-5.31%	-6.81%	-34.61%	-38.95%	6.81B
SINOPHARM GROUP CO. LTD.	+2.34%	-0.92%	-12.08%	-33.50%	6.28B
H. LUNDBECK A/S	+1.43%	+2.01%	+17.05%	+32.59%	6.18B
GALENICA AG	+0.35%	+1.84%	-1.21%	+20.00%	5.28B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	-4.35%	-4.35%	-9.77%	-16.95%	3.39B
Average	-0.77%	-1.30%	-7.48%	+45.74%	20.27B
Weighted average by Cap.	+0.23%	+2.27%	+11.50%	+103.03%

	2026 *	2027 *
Net sales	5.12M 4.49M 4.14M 3.88M 7.27M 483M 7.42M 49.77M 19.26M 239M 19.24M 18.82M 828M	17.22M 15.1M 13.91M 13.03M 24.43M 1.62B 24.94M 167M 64.72M 803M 64.65M 63.24M 2.78B
Net income	-12.52M -10.98M -10.12M -9.47M -17.76M -1.18B -18.13M -122M -47.05M -584M -47.01M -45.98M -2.02B	-2.81M -2.47M -2.27M -2.13M -3.99M -265M -4.08M -27.34M -10.58M -131M -10.57M -10.34M -455M
Net Debt	-	-